University at Buffalo - The State University of New York
Skip to Content
UBMD Physicians' Group

Clinical Trials

Teriflunomide (Aubagio) Effects on Cognitive and Vocational Outcomes, as Related to Neurodegeneration in Multiple Sclerosis: A prospective, observational, single-blinded study.

The purpose of this study is define the effect of teriflunomide (Aubagio) on cognitive abilities in patients with relapsing multiple sclerosis (MS). This study also seeks to [a] relate changes in cognition to vocational problems, and [b] determine MRI correlates of change in cognition, more specifically gray-matter (GM) volume metrics which we believe reflect neurodegeneration.

Eligibility

Patients must be new to teriflunomide therapy and diagnosed with MS with a relapsing disease course between the ages of 18-60.

Requirements

Patients on teriflunomide receive an initial neurological and neuropsychological examination and come back for a follow-up neurological and neuropsychological evaluation after 12 months and 24 months. Patients are also asked to take an online vocational monitoring survey every 3 months.

Reimbursement

Patients receive $125 after each in person assessment. They will receive a $15 gift card after each completion of the web based survey. A total of $495 will be given as compensation if all study visits are completed over 2 years.

Investigator

Ralph H.B. Benedict, PhD

Contact Information

Name: Ralph H.B. Benedict
Phone: 716-799-9064
Email: benedict@buffalo.edu